Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
Journal: Blood advances
Published: December 09, 2024
Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.
Journal: Blood advances
Published: December 02, 2024
Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL.
Journal: International journal of hematology
Published: August 23, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
Journal: Future oncology (London, England)
Published: July 29, 2024
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.
Journal: Blood advances
Published: July 16, 2024
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Journal: Blood cancer journal
Published: December 29, 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Journal: Future oncology (London, England)
Published: December 13, 2023
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
Journal: Blood advances
Published: September 22, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 21, 2023
Last Updated: 09/26/2026